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Human adipose stem cell differentiation is highly
affected by cancer cells both in vitro and in vivo:
implication for autologous fat grafting
Francesca Paino1,4, Marcella La Noce1,4, Diego Di Nucci2, Giovanni Francesco Nicoletti3, Rosa Salzillo3, Alfredo De Rosa3,
Giuseppe Andrea Ferraro3, Gianpaolo Papaccio*,1, Vincenzo Desiderio1,5 and Virginia Tirino1,5
Recent studies showed that mesenchymal stem cells derived from adipose tissue can promote tumour progression, raising some
concerns regarding their use in regenerative medicine. In this context, we co-cultured either SAOS2 osteosarcoma or MCF7 breast
cancer cells with human adipose stem cells (hASCs), in order to evaluate potential effects of cancer cells on hASCs differentiation,
in vitro and in vivo. In this study we observed that both SAOS2 and MCF7 cell lines induced an increase in hASCs proliferation,
compared to hASCs alone, but, surprisingly, neither changes in the expression of CD90, CD29, CD324 and vimentin, nor variations
in the Twist and Slug mRNAs were detectable. Noteworthy, SAOS2 and MCF7 cells induced in hASCs an upregulation of CD34
expression and stemness genes, including OCT3/4, Nanog, Sox2 and leptin, and a decrease in angiogenic factors, including CD31,
PDGFα, PDGFRα, PDGFRβ and VEGF. SMAD and pSMAD2/3 increased only in hASCs alone. After 21 days of co-culture, hASCs
differentiated both in adipocytes and endothelial cells. Moreover, co-injection of MCF7 cells with hASCs led to the formation of a
highly vascularized tumour. Taken together our findings suggest that mesenchymal stem cells, under tumour cell induction, do not
differentiate in vitro or facilitate the angiogenesis of the tumour in vivo, thus opening interesting new scenarios in the relationship
between cancer and stem cells. These findings may also lead to greater caution, when managing autologous fat grafts in cancer
patients.
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Several studies1-4 suggested that mesenchymal stem cells
(MSCs) participate in tumour development through their
homing ability towards the primary tumour and metastatic
site, thus playing a pivotal role in tumour progression. One of
the physiologic roles of MSCs is being recruited towards the
site of wound healing in order to repair injured tissues. The
same mechanism is applied to tumours including breast
cancer, glioma and osteosarcoma.5–7 In fact, Dvorak8 defined
cancer as a ‘wound that never heals’, stating that the tumour
microenvironment is similar to the environment of an injured
tissue.
MSCs secrete chemokines, cytokines and growth factors
that lead to an inflammatory state, aimed at improving
physiological tissue regeneration following injury. However,
inflammation also contributes and supports tumorigenesis
andmetastasis favouring homing of disseminated tumour cells
in new tissues.9 Cytokines and growth factorsmediate a cross-
talk between epithelial cells and surrounding stromal cells that
are crucial for cancer initiation, progression and metastases
formation.10–12 Some factors, such as PDGF and VEGF,
released in the tumour microenvironment, can promote
tumour neoangiogenesis through the differentiation of
endothelial progenitors into new vessels.13,14
Human adipose tissue is a rich source of multipotent
MSCs, termed adipose stem cells (hASCs). hASCs are
phenotypically similar to bone marrow-MSCs and share
multipotentiality, proliferation and the ability to differentiate
into mesenchymal lineages. We previously selected hASCs
using the CD34 and CD90 markers.15 These cells are able to
differentiate in multivacuolar adipocytes and endothelial cells
forming capillary-like structures in methylcellulose.15 In long-
term cultures and in murine models, they form vascularized
adipose tissue surrounded by connective tissue.16,17 More-
over, hASCs, positive for CD34 and NG2 markers and loaded
in vivo on a cross-linked hyaluronic acid-Lys scaffold, are also
able to fabricate skeletal muscle tissue.18
Several reports have described that hASCs show regen-
erative aptitudes in several clinical fields including plastic,
orthopaedic, cardiac, bone and breast surgery, promoting
tissue repair.19–21
Therefore, hASCs could be promising candidates for
reconstructive cellular therapy in patients with cancer history,
but the potential risk of promoting tumour reactivation is
controversial.
In fact, although hASCs demonstrated good aesthetic
results, they could be promoters of cancer recurrence.22,23
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Little is known about the underlying molecular mechanisms
that link MSCs to tumour cells in the tumour microenviron-
ment. The strict involvement of such interactions has not yet
been completely elucidated and some concerns remain
regarding the MSCs’ potential tumour-suppressive effect or
their role in favouring and enhancing tumour development.
In this context, we aimed to ascertain whether mesenchy-
mal and/or epithelial cancer cells may exert any influence
upon MSCs derived from adipose tissue. To address this
issue, we used a cancer cell line derived from breast cancer,
MCF7, and one derived from osteosarcoma, SAOS2, co-
culturing both of them with hASCs. In this way, we established
amodel in whichwemimicked the influence of epithelial and/or
mesenchymal cancer cells on MSCs microenvironment.
Results
MCF7 and SAOS2 cells induced morphologic changes
and an increase in hASCs proliferation. Independent of
culture time, MCF7 and SAOS2 cells in co-cultures led to
hASCs morphological alteration. After 3 days of co-culture,
MCF7 cells induced the formation of a mixed cell population
with elongated and polygonal hASCs cells, as demonstrated
by the distribution of vimentin, when compared to hASCs
cultured alone (Figures 1a–e). Conversely, SAOS2 cells
induced a swelling of hASCs with an epithelioid and/or
poligonal shape (Figure 1f), as demonstrated by vimentin
distribution. Moreover, hASCs co-cultured with MCF7 cells
showed a growth in bundles similar to those of fibroblasts,
whereas hASCs co-cultured with SAOS2 cells exhibited a
growth in carpet similar to that of epithelial cells (Figures 1e
and f).
Regarding proliferation, growth curves, at both short and
long time courses were performed. In both cases, SAOS2 and
MCF7 cells induced a higher proliferation rate of co-cultured
hASCs than hASCs alone. In fact, mean doubling times were
72, 36 and 24 h for hASCs alone, co-cultured with SAOS2 and
MCF7, respectively (Figure 1g). Cell cycle analyses also
confirmed this result (Figure 1h). hASCs co-cultured with
MCF7 and SAOS2 were distributed mainly in S and G2M
phases with respect to hASCs cultured alone with mean
percentages of 38% of cells in S phase and 18% inG2M phase
for the co-culture with MCF7, and 17% of cells in S phase and
10% in G2M phase for the co-culture with SAOS2. hASCs co-
cultured alone were mostly distributed in G0G1 phase with a
mean percentage of 92 (Figure 1h).
MCF7 and SAOS2 cells induced an alteration in CD34
expression in hASCs. In order to investigate the possible
change in the phenotype, cytometric analysis for mesench-
ymal markers was performed. CD90, CD29 and vimentin
expression were similar in all conditions tested with a mean
distribution of approximatively 98% (Figures 2a–c). CD34, an
epithelial marker and correlated with epithelial to mesench-
ymal transition, was negative both in hASCs alone and when
co-cultured with cancer cells (Figure 2d). Nevertheless, it is
noteworthy that a strong variation in CD34 expression was
observed (Figure 2d).
At 7 days, MCF7 cells induced an upregulation of CD34
expression compared to both hASCs cultured alone and
hASCs co-cultured with SAOS2 cells. At 14 days, they led to a
drastic decrease that was stably maintained up to 21 days. On
the contrary, at 7 days, SAOS2 cells induced a severe
decrease of CD34 expression, an increase at 14 days
compared to hASCs cultured alone and a slight decrease at
21 days. At this time, interestingly, albeit the cancer cell-
induced decrease, CD34 expression was always higher than
that expressed by hASCs cultured alone; furthermore, Saos2
cells led to a greater increase in CD34 expression when
compared to the MCF7 cells (Figure 2d).
Further investigations of CD34 expression were also
performed using RT-PCR (Figure 3). CD34 mRNA levels
showed the same trend compared to the one of cytometric
analyses. Also in this case, MCF7 cells co-cultured with
hASCs induced a strong increase in CD34 mRNA levels at
7 days, a decrease at 14 days and a substantial upregulation
at 21 days (Figures 3a–c). For Saos2 cells co-cultured with
hASCs, CD34 mRNA levels decreased at 7 days (Figure 3a),
increased at 14 days and were always lower than those of
hASCs cultured alone (Figure 3b). At 21 days, SAOS2 cells
led to a tremendous upregulation of CD34 mRNA levels,
compared to those expressed by hASCs cultured alone
(Figure 3c). In summary, both MCF7 and SAOS2 induced in
hASCs an increase of CD34 marker at both the protein and
gene levels.
MCF7 and SAOS2 cells induced an upregulation of Sox2,
Nanog, OCT3/4 and leptin in hASCs. With the purpose of
better understanding the effects of cancer cells on hASCs’
stemness setting, RT-PCR analyses were performed for
stemness genes, including Sox2, Nanog and OCT3/4
(Figure 3). MCF7 cells led to an increase of all stemness
genes, Sox2, Nanog and OCT3/4, both during culture and
compared to those expressed by hASCs cultured alone.
Regarding the effects induced on hASCs, at 7 days, SAOS2
cells induced an upregulation of all three genes of stemness,
compared to those expressed by hASCs cultured alone. At
14 days, these genes decreased and no differences were
detectable for Sox2 and Nanog between hASCs cultured
alone and co-cultured with SAOS2, whereas OCT3/4
decreased with respect to the values found at 7 days, but
were found to be still higher than those expressed by hASCs
alone. At 21 days, SAOS2 cells surprisingly induced a strong
upregulation of Sox2, Nanog and OCT3/4 mRNA levels
compared to those of hASCs cultured alone (Figure 3).
Leptin is a growth factor involved specifically in breast
tumorigenesis and is produced by hASCs. Interestingly, leptin
mRNA levels were increased in hASCs co-cultured both with
MCF7 and SAOS2 with respect to those of hASCs cultured
alone. Moreover, MCF7 induced a stronger increase of leptin
expression than those promoted by SAOS2 cells in hASCs
(Figure 3).
In order to evaluate EMT/MET-related genes, TWIST and
Slug were analysed by semi-quantitative PCR. No differences
were detectable between hASCs cultured alone and those co-
cultured with MCF7 and SAOS2 cells (data not shown).
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MCF7 and SAOS2 cells induced a downregulation of
angiogenic factors in hASCs. With the aim of evaluating
the effects of cancer cells upon the hASCs’ capability of
promoting angiogenesis, CD31, VEGF, PDGFA, PDGFRα,
PDGFRβ gene expression was analysed at 7, 14 and 21 days
(Figure 4). At 7 days, MCF7 cells induced a downregulation of
every angiogenic factor except for PDGFRβ in hASCs, when
compared to those of hASCs cultured alone. At 14 days, only
an increase in the CD31 mRNA level was detected. VEGF
mRNA levels remained similar for hASCs co-cultured with
MCF7 and hASCs cultured alone. PDGFA, PDGFRα,
PDGFRβ genes showed a decrease. At 21 days, MCF7 led
Figure 1 Morphological changes and proliferation in hASCs after cancer cells treatment. (a–c) Isotypes controls for immunofluorescence assay on hASCs cultured alone,
co-cultured with MCF7 and co-cultured with SAOS2, respectively. (d) Vimentin expression on hASCs cultured alone, in the inset, a magnification of hASCs showing typical
morphology of fibroblast like cells. (e) Vimentin expression on hASCs co-cultured with MCF7 cells, in the inset, a magnification of hASCs showing a mixed morphology of
polygonal and elongated cells. (f) Vimentin expression on hASCs co-cultured with SAOS2 cells, in the inset, magnification of hASCs showing a morphology of polygonal cells. (g)
Growth curves at 72 h and 21 days showing proliferation rate of hASCs co-cultured with cancer cells greater than those of hASCs cultured alone. (h) Cell cycle analyses showing
that hASCs co-cultured with cancer cells are most distributed in S and G2M phases. Scale bar= 400 μm; inset: scale bar= 100 μm. Results are represented as mean±S.E.M.
of three independent experiments. *Po0.01; **Po0.001
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to a downregulation of all markers except for VEGF mRNA
level compared to those of hASCs cultured alone (Figure 4a).
On the other hand, SAOS2 cells induced in hASCs an
increase in only VEGF mRNA levels at 7 days, an
increase in CD31 mRNA levels at 14 days, and a strong
decrease in all angiogenic factors except for VEGF mRNA
levels at 21 days compared to those of hASCs cultured alone
(Figure 4a).
In addition, during culture, hASCs cultured alone showed a
strong increase in angiogenic factors indicating their differ-
entiation versus the angiogenic lineage. Also in hASCs co-
cultured with MCF7 and SAOS2 cells, it was possible to
observe a similar trend, but with a slower increase in
angiogenic genes compared to those observed in hASCs
cultured alone (Figure 4b).
To further characterize angiogenic differentiation, expres-
sion of CD31 and VEGF proteins were analysed at 7, 14 and
21 days by western blotting. In accordance with gene
expression analyses, cancer cells induced a decrease both
of CD31 andVEGF in hASCs in comparison to those of hASCs
cultured alone, reinforcing the hypothesis of angiogenic
inhibition induced by cancer cells. In particular, at 7 days,
SAOS2 induced an increase of CD31 expression respect to
those of hASCs cultured alone, whereas at 14 and 21 days,
CD31 expression decreased. MCF7 induced a strong
decrease at all-time points in comparison to those of hASCs
cultured alone. For VEGF expression at 7 days, only hASCs,
cultured alone, showed a weak expression of this marker. At
14 and 21 days, both SAOS2 and MCF7 cells induced a
drastic decrease of VEGF protein compared to those of
hASCs cultured alone (Figure 4c).
Adipogenic and angiogenic differentiation evaluation.
After 21 days of co-culture, hASCs were tested for their ability
to differentiate using an adipogenic medium for adipogenic
differentiation and matrigel for angiogenic differentiation for
7 and 15 days, respectively (Figure 5). hASCs cultured alone
were not able to form multivacuolar adipocytes. The cells
Figure 2 Cytometric analyses of hASCs co-cultured alone and cancer cells. (a) CD90, CD29, vimentin, CD324 and CD34 expressions on hASCs at 7. (b) 14 and (c) 21 days
showing no variation of CD90, CD29 and vimentin markers. CD324 expression is negative. (d) Cancer cells induce an upregulation of CD34 at 21 days.*Po0.005, **Po0.001,
***Po0.0005 compared to the parental cell line. Results are represented as mean± S.E.M. of three independent experiments
Figure 3 Semiquantitative PCR analyses of stemness markers. (a) CD34, Sox2, Nanog, Oct3/4 and leptin mRNA levels on hASCs co-cultured alone and with cancer cells
at 7. (b) 14 and (c) 21 days showing cancer cells induce an increase of stemness factors in hASCs.*Po0.005, **Po0.001, ***Po0.0005 compared to the parental cell line.
Results are represented as mean± S.E.M. of three independent experiments
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were negative for adiponectin and no formation of intracellular
lipid droplets was detectable. They showed an elongated
shape, similar to fibroblasts (Figure 5a). On the contrary,
hASCs co-cultured with both MCF7 and SAOS2 cells,
acquired a typical morphology of adipocytes with lipid
droplets, positive for adiponectin, confirming adipogenic
differentiation (Figures 5b and c). For the angiogenic
differentiation, hASCs alone were not able to form a vascular
network. The cells were spread on matrigel without acquiring
any morphological changes in structures that were like
vessels (Figure 5d). Conversely, hASCs co-cultured with
MCF7 and SAOS2 cells formed a network of intercellular
tubes including cells with endothelial morphology, thus
confirming their angiogenic differentiation (Figures 5e and f).
MCF7 and SAOS2 induced a downregulation of
p-SMAD2/3 in hASCs. In order to investigate the effect of
cancer cells on SMAD2/3 and its phosphorylated form, a
western blot assay was performed on hASCs cultured alone
and with MCF7 and SAOS2 at 7, 14 and 21 days (Figure 6).
hASCs cultured alone showed a strong increase of both
SMAD2/3 and p-SMAD2/3 over the culture period and
p-SMAD2/3 levels increased dramatically at 21 days. hASCs
co-cultured with MCF7 and SAOS2 cells always expressed
lower levels of both SMAD2/3 and p-SMAD2/3 compared to
hASCs cultured alone. In particular, MCF7 cells induced a
decrease in p-SMAD2/3 during culture time when co-cultured
with hASCs, whereas SAOS2 cells led to a peak of
p-SMAD2/3 at 14 days followed by a decrease at 21 days
in co-cultured hASCs (Figure 6). In summary, p-SMAD2/3
was activated only in hASCs cultured alone.
Co-injection of MCF7 and hASCs promoted tumour
formation in xenografts. MSCs home into the human
tissue stroma for tissue regeneration. To evaluate whether
the co-injection of MCF7 cells with hASCs could influence the
behaviour of MCF7 breast cancer cells, in vivo tumorigenicity
was analysed. hASCs were not tumorigenic per se; however,
they revealed a tumorigenic potential in the presence of
MCF7 cells. In fact, both MCF7 cells and MCF7 co-injected
with hASCs formed tumours in mice after 30 days. Moreover,
although both MCF7 cells alone and MCF7 co-injected
Figure 4 Semiquantitative PCR and western blot analyses of endothelial markers. (a) Variation of CD31, VEGF, PDGFA, PDGFRα, PDGFRβ mRNA levels at 7, 14 and
21 days showing cancer cells induce a downregulation of CD31, PDGFA, PDGFRα, PDGFRβ gene expression, and an upregulation VEGF levels in hASCs. (b) Variation of
CD31, VEGF, PDGFA, PDGFRα, PDGFRβmRNA levels in culture time showing endothelial gene expression increases in hASCs alone. (c) Variation of CD31 and VEGF protein
levels at 7, 14 and 21 days showing a decrease of these markers in hASCs induced by cancer cells. The protein amount was normalized to β-tubulin and evaluated using
densitometry histogram. *Po0.005, **Po0.001, ***Po0.0005 compared to the parental cell line. Results are represented as mean±S.E.M. of three independent experiments
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hASCs had the capability to regenerate tumours, the ratio of
tumour size and growth of MCF7 with hASCs cells were
significantly greater than those of MCF7 cells alone
(Figures 7a–c). MCF7 cells with hASCs gave rise to 10-fold
greater tumour sizes than those detected in MCF7 cells alone
(Figure 7c). Hematoxylin and eosin (H&E) staining revealed
that xenografted tumours consistently reproduced the original
human mammary tumour (Figures 7d and e), as confirmed
also by positive staining for class I HLA (Figure 7f). Moreover,
xenograft tumours derived from the co-injection of MCF7 with
hASCs were highly vascularized. Xenografted tumours arose
from the injection of MCF7 cells alone showed positivity for
class I HLA, thus confirming human origin, negativity for
CD31, positivity for VEGF and cytokeratin, and negativity for
vimentin (Figures 7f–j). On the other hand, xenografts derived
from co-injection of MCF7 cells with hASCs exhibited
positivity for class I HLA, CD31, VEGF and slightly positive
for vimentin and cytokeratin (Figures 7k–o).
Discussion
MSCs derived from adipose tissue represent a promising
cell source for regenerative therapies. Recent studies demon-
strated that hASCs can improve graft retention.24,25 However,
the risks linked to cell treatment still remain unclear,
particularly in the context of patients affected by pre-existing
cancer.26,27 MSCs derived from adipose tissue could serve as
a primary MSC source for cancer contributing to the tumour
microenvironment and thus playing a role both in epithelial and
mesenchymal carcinogenesis.28 Therefore, it is likely that
adipose tissues adjacent to the tumour may be a more
significant contributor of hASCs for cancer progression. All
studies of literature have shown, up to now, the effects of
Figure 5 Evaluation of hASCs differentiation ability by immunohistochemical analysis. (a) Negative expression of adiponectin on hASCs. (b) Strong positivity of adiponectin
on hASCs co-cultured with MCF7. (c) Positivity for adiponectin on hASCs co-cultured with SAOS2. (d) hASCs alone are not able to form a vascular network in matrigel medium;
(e) hASCs co-cultured with MCF7 formed intercellular tubes network with endothelial morphology (arrows). (f) hASCs co-cultured with SAOS2 formed structures similar to
capillary like tubes (arrows). Scale bar= 50 μm
Figure 6 Western blot analysis and densitometry evaluation of SMAD2/3 and p-SMAD2/3. pSMAD2/3 was activated only in hASCs cultured alone. The protein amount was
normalized to tubulin. *Po0.005, **Po0.001, compared to the parental cell line. Results are represented as mean± S.E.M. of three independent experiments
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MSCs on cancer cells.2,5,17–21 Our aim was, on the contrary, to
investigate the effects that cancer cells of both epithelial and
mesenchymal origin may exert on hASCs still present after
tumour resection, a not uncommon scenario. To address this
issue, we used MCF7 cells in order to mimic the tumour
microenvironment of mammary glands surrounded by adipose
tissue with its resident adipose stem cells and SAOS2 cells to
mimic the stromal tissue sustaining mesenchymal tumours.
We established a co-culture system using inserts of 0.4 μm.
We found that both MCF7 and SAOS2 stimulated
hASCs increasing their proliferation. In fact they showed an
almost halved doubling time, being distributed in S-G2M phase
of the cell cycle, compared to hASCs cultured alone. Thus,
the first effect of tumour cells on stem cells was to increase
their proliferation. One hypothesis is that cancer cells
could induce such an effect with the purpose to increase the
number of stem cells that will then be beneficial to the tumour
itself in order to favour specific processes ranging from growth
of vessels to metastases. Generally, when stem cells
proliferate, they differentiate in a specific lineage. In previous
studies,15–17 we demonstrated that hASCs differentiate in
endothelial cells without inducing factors. Therefore, we
investigated a series of markers involved in stemness
maintenance, EMT/MrET processes and differentiation. No
changeswere detectable for mesenchymal markers except for
the CD34 marker.
Figure 7 Xenograft evaluation. (a, b) Xenografted tumour derived from implantation of MCF7 alone and MCF7 with hASCs. (c) Xenografted tumour growth curves show that
the injection of MCF7 with hASCs form tumours with major efficiency in comparison with injection of MCF7 alone. (d, e) H&E staining of xenografted tumour derived from
implantation of MCF7 alone and MCF7 with hASCs. Scale bar= 400 μm. (f-j) Positivity for I Class HLA, negativity for CD31, positivity for VEGF and cytokeratin, negativity for
vimentin on xenografted tumour derived from implantation of MCF7 alone. (k-o) Positivity for I Class HLA, CD31, VEGF, cytokeratin and vimentin on xenografted tumour sample
derived from implantation of MCF7 with hASCs. Arrows indicate blood vessels. Scale bar= 50 μm. **Po0.001, ***Po0.0005 compared to the parental cell line. Results are
represented as mean±S.E.M. of three independent experiments
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CD34 is a master marker by which hASCs are isolated from
the vascular stromal fraction of adipose tissue.15–17 They are
expressed by hematopoietic stem cells and endothelial and
mesenchymal cells of different healthy tissues.29,30 The
expression of CD34 has been extensively studied in the
reactive stroma of many types of cancer, particularly in breast
cancer.31,32 In normal tissues, CD34+ fibroblasts are pre-
dominantly located in the region surrounding small vessels
adjacent to the basal lamina of the epithelial layer.33 Some
authors suggested that CD34+ fibroblasts in breast and
sarcoma lesions are recruited through the bloodstream.32,34
In general, hASCs show an increase in CD34 expression and
then a decrease during differentiation.15 This biological
behaviour was not observed for hASCs co-cultured with
cancer cells in that an increase in the induction of CD34 was
observed. Another interesting consideration is that stemness
factors including NANOG, OCT3/4 and Sox2 increased in
concordance with CD34 during cell culture. Cancer cells, both
MCF7 and SAOS2, induced both an upregulation and the
maintenance of stemness of hASCs during culture. This
important result was confirmed by a decrease of p-SMAD2/3.
Singh and colleagues35showed that when the phosphoryla-
tion level of SMAD2/3 decreased, the level of Nanog
increased, and consequently the differentiation decreased.
The induction and maintenance of a stem phenotype are also
confirmed by the evidence that the mesenchymal-epithelial
transition (MET) is not induced. In our study, MET-related
markers including CD324, Slug, Twist and vimentin did not
change after cancer cell treatment.
Therefore, we suppose that cancer cells, independent from
their origin, induce the maintenance of stemness and stability
of hASCs in the microenvironment in which they live without
the activation of migration signalling. This is of paramount
importance because for the cancer cell it is easier to use a
stem cell, resident in its microenvironment, than to recruit it
from bone marrow. The hASCs’ stemness phenotype was
confirmed also by the endothelial/angiogenic gene expression
analyses, as well as by CD31 and VEGF proteins analyses,
which clearly showed that these factors were upregulated in
hASCs cultured alone and strongly downregulated in hASCs
co-cultured with cancer cells, thereby reinforcing the hypoth-
esis of a ‘stemness steady state’ or maintenance. Another
stemness feature is linked to the ability to differentiate. hASCs,
after co-culture with cancer cells, were able to differentiate into
adipocytes and endothelial cells. hASCs cultured alone were
not able to form adipocyte and capillary-like structures.
Additionally, in order to understand the role of hASCs in
tumour growth, we performed a tumorigenesis assay.We used
only MCF7 cells and not SAOS2 cells because it is well known
that these cells do not grow in murine models. Co-injection of
MCF7 cells and hASCs into nude mice suggested that hASCs
did not differentiate in adipocytes, but theywere integrated into
the tumour stroma subsequently forming tumours that grew
faster and bigger than those originating from MCF7 cells
alone, thus reinforcing the hypothesis that hASCs have the
capability of sustaining tumour growth. Furthermore, tumours
derived from co-injection of MCF7 and ASCs were vascular-
ized being VEGFandCD31 highly expressed. Our hypothesis,
therefore, is that cancer cells of both epithelial and mesench-
ymal origin release factors to induce and maintain a stem cell
phenotype in hASCs, which modify their programme of
differentiation with the purpose of assisting the tumour in its
development, contributing to the formation of new blood
vessels. The creation of a stemmicroenvironment surrounding
the tumour mass appears to be a possible mechanism to
explain the survival and growth of the tumour. Cancer cells and
stem cells share several biological properties, and transcrip-
tional factors that monitor the fate of stem cells could play a
major role in the renewal of cells modified from the cancerous
microenvironment. Therefore, the induction and maintenance
of a stemness phenotype in mesenchymal cells might be a
further mechanism of survival and resistance to drugs
implemented by the tumour. The identification of factors
secreted by cancer cells that induce such changes or specific
markers that characterize the new modified cells could be
useful in strengthening the conventional treatments and
combat the relapse of the disease.
In conclusion, our study addresses for the first time that
cancer cells are able to maintain hASCs in a ‘stemness state’.
Thus, if cancer cells persist following surgery, they will most
likely induce resident hASCs to promote tumour angiogenesis,
thus exacerbating tumour growth and aggressiveness. Con-
sequently, adipose grafts may give rise, in the case of cancer
cell persistence after surgery (a rather common event), to
tumour growth. Therefore, it must be strongly discouraged in
groups of patients including those undergoing:adipose graft
after a breast cancer for mastoplasty; adipose graft, following
cancer in general for every treatment.
In these circumstances, the use of adipose tissue for auto-
grafting must be carefully performed, only after meticulous
analyses of possible cancer. Also the cases of an early cancer,
which is made of only a few cells, though not yet detectable,
must be regarded as a possible side effect or contro-indication
and the informed consent must include this prospect.
This work highlights the biological elucidation for those
clinical cases reporting a fast-growing and more aggressive
recurrence subsequent to fat grafting in patients with a history
of cancer.
Materials and Methods
Ethics statement. All animal experiments were conducted in full compliance
with Second University of Naples and Italian Legislation for Animal Care.
Cell culture. SAOS2 and MCF7 cell lines were purchased from ATCC cell bank;
cells were placed in DMEM culture medium (Gibco, Rodano, Milan, Italy),
supplemented with 10% FBS (Gibco, Rodano, Milan, Italy), 100 mM 2 P-ascorbic
acid, 2 mM L-glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin (all purchased
from Invitrogen, Life Technologies Italia, Monza, Italy) and placed in 75 ml flasks
with filtered valves. Flasks were incubated at 37 °C in 5% CO2 and the medium was
changed twice a week. At confluence, cells were subdivided into new flasks until the
end of the experiment.
Adipose tissue collection and cell culture. Subcutaneous adipose
tissue from abdomen and breast was obtained following written informed consent,
approved by our Internal Ethical Committee (Second University Ethical Committee),
from patients with a mean age of 37± 2.5 years. Adipose tissue was obtained
through lipectomy or liposuction in the Plastic and Reconstructive Surgery Division
of the Second University of Naples. The adipose tissue was placed in a
physiological solution (0.9% NaCl), washed twice in PBS, minced, and placed in a
digestion solution: collagenase type I (3 mg/ml; Gibco, Rodano, Milan, Italy) and
dispase (4 mg/ml; Gibco, Rodano, Milan, Italy) at 37 °C for 60 min in a shaking
water bath. The digest was filtered through 70 μm filters (Becton & Dickinson,
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Sunnyvale, CA, USA). After filtration and washing, the pellet was re-suspended in
erythrocyte lysis buffer (155 mM NH4Cl, 10 mM KHCO3, 0.1 mM EDTA, pH 7.3) for
10 min at room temperature. The cell suspension was centrifuged at 1300 rpm for
7 min and the pellet re-suspended in DMEM at 10% FBS in 25 cm2 flasks. hASCs
were isolated and characterized by immunophenotype as previously described in
De Francesco et al.15 hASCs were used at first passage of culture. Flasks were
incubated at 37 °C under 5% CO2 and the medium changed twice a week. Cells
reached confluence in 5–7 days.
Co-cultures. hASCs and SAOS2 or MCF7 cells were plated in co-culture in
equal numbers with a 0.4 μm insert (Nunc, Thermo-Fisher Scientific, Milan, Italy) in
DMEM at 10% FBS. hASCs were plated at 1° passage of culture, 10 000 cell/well in
quadruplicates. hASCs in standard culture condition were used as control cell lines.
Growth and cell cycle analyses. hASCs alone and co-cultured with
SAOS2 and MCF7 cells were plated at a density of 20 × 104 cells/well in six-well
plates. At 24, 48 and 72 h and 7, 14 and 21 days, cells were harvested and
re-suspended in PBS. An aliquot of cell suspension was diluted with 0.4% trypan
blue (Sigma-Aldrich, Milan, Italy), pipetted onto a haemocytometer and counted
under a microscope at × 200 magnification. Live cells excluded the dye, whereas
dead cells take up the dye and consequently stained intensely with trypan blue. The
number of viable cells for each experimental condition were counted and
represented on a linear graph. The doubling time (DT) was determined from the
growth curves or by using the formula:
DT ¼ t–t 0ð Þlog 2= log N– log N0ð Þ
where t and t0 were the times at which the cells were counted, and N and N0 were
the cell numbers at times t and t0, respectively. Experiments were repeated three
times with three triplicates for each experiment.
Cell cycle anlysis assay was performed using flow cytometry. After 72 h of
co-culture, hASCs, cultured alone and with MCF7 and SAOS2 cells, were harvested
in PBS containing 2 mM EDTA, washed once with PBS, fixed in iced ethanol 70% and
incubated with 25 μg/ml PI (Sigma-Aldrich) plus Rnasi 1 mg/ml for 120 min at 4 °C in
the dark. Stained nuclei were analysed with a FACS Aria III (Becton & Dickinson,
Mountain View, CA, USA), and the data analysed using a ModFit 2.0 cell cycle
analysis software (Verity Software House, Topsham, UK ). Experiments were
repeated three times with three triplicates for each experiment.
Flow cytometry. Following isolation, the cells were expanded in vitro and then
characterized with flow cytometry in order to evaluate the cell surface marker
expression at 7, 14 and 21 days of co-culture both with SAOS2 and MCF7 cells.
hASCs were characterized with antibodies against the following markers: CD90
FITC, CD34 PE, CD29 PECy5.5, CD44 FITC, CD324 PE and vimentin (from BD
Pharmingen, Milan, Italy). For staining, the antibodies were incubated for 30 min at
4 °C. After washing, cells were re-suspended in PBS. For intracellular staining of
vimentin, Fix & Perm kit (Invitrogen, Life Technologies Italia) was used following the
manufacturer’s instructions. All samples were analysed using Diva Software for flow
cytometer FACS ARIA III (BD Pharmingen). Statistical evaluation was obtained from
three independent experiments. Standard deviation was indicated by error bars.
Immunofluorescence. hASCs cultured alone and co-cultured with SAOS2
and MCF7 cells were fixed with 4% paraformaldehyde, permeabilized with TRITON
X-100 and blocked with bovine serum albumin at 5% for 1 h at room temperature
and then stained with primary antibodies at 4 °C overnight. The primary antibody
used was mouse anti-human vimentin (Invitrogen, Life Technologies Italia). The
secondary antibody, goat anti-mouse FITC (Abcam, Cambridge, UK) diluted 1:200
in PBS, was incubated for 60 min at 4 °C, and the Hoechst33342 (Invitrogen, Life
Technologies Italia) was used to stain the nucleus and was incubated for 7 min at
room temperature. Cells were observed under the fluorescence microscope (EVOS,
Life Technologies, Milan, Italy). Isotypes and non-probed cells were used as
controls.
Adipogenic differentiation. After 21 days of co-culture with MCF7 and
SAOS2 cells, hASCs were induced in the following adipogenic medium for
2–3 weeks: DMEM supplemented with 10% FBS plus dexamethasone (1 mM;
Sigma-Aldrich), human recombinant insulin (10 mM; Sigma-Aldrich), indomethacin
(200 mM; Fluka, Milan, Italy) and 3-isobutyl-1-methyl-xantine (IBMX) (0.5 mM;
Sigma-Aldrich). Cells cultured in basal medium were used as controls. To confirm
the adipogenic differentiation, cells were fixed with 4% paraformaldehyde (Sigma-
Aldrich) for 10 min at 4 °C, washed in PBS and stained with primary antibody
mouse anti-human adiponectin (Abcam) diluted 1:100 in PBS for 30 min at 4 °C
using an Abcam Kit (Abcam), according to the manufacturer’s instructions. The
nuclei were stained with haematoxylin and the cells were observed under an
inverted light microscope.
Angiogenic differentiation. After 21 days of co-culture with MCF7 and
SAOS2 cells, to analyse in vitro capillary-like morphology, hASCs were plated in
24-well plates in a semi-solid growth medium that consisted of matrigel in DMEM,
20% FBS, 1% bovine serum albumin, 1024 mol/L mercaptoethanol (Sigma-Aldrich)
and 2 mmol/L L-glutammine (Gibco, Rodano, Milan, Italy). All cultures were
performed in triplicate, incubated at 37 °C under 5% CO2 and left for 7 days to
develop a capillary-like morphology.
RNA extraction and RT-PCR. Total RNA was extracted from ASCs after 7,
14 and 21 days of culture in DMEM supplemented with 10% FBS, 10% FBS New
Zealand or 10% HS, using an AMBION kit (Life Technologies Italia) following the
manufacturer’s instructions. RNA was treated with DNase (Promega, Milan, Italy) to
exclude DNA contamination and stored at − 80 °C until required. cDNA synthesis
was carried out from total RNA (1 μg) using VILO SUPERSCRIPT (Invitrogen, Life
Technologies Italia). PCR analyses were carried out using a BIOER Life Pro thermal
cycler (Life Technologies Italia) in which samples underwent a 2-min denaturing
step at 94 °C, followed by 35 cycles of 94 °C for 30 s, 52–60 °C for 60 s, 72 °C for
30 s, and a final extension step at 72 °C for 4 min. Each PCR reaction was
performed in a total volume of 12.5 μl containing Tris buffer 10 mM pH 8, 0.2 mM of
each dNTP, 1.5 mM MgCl2, and 0.2 μM of each primer, Taq DNA polymerase 1 U
and 1 μl of each cDNA. PCR was performed using the following primer sequences
and PCR product annealing: GAPDH, fw: GGAGTCAACGGATTTGGTCG, rev:
CTTCCCGTTCTCAGCCTTGA, 57 °C; CD34, fw: TCAAATGTTCAGGCATCAGAG,
rev: TCAGGTCAGATTGGTGCTT, 56 °C; NANOG, fw: TTCAGTCTGGACACT
GGCTG, rev: CTCGGTGATTAGGGTCCAAC, 58 °C; SOX-2, fw: CGATGCCGAC
AAGAAAACTT, rev: CAAACTTCCTGCAAAGCTCC, 58 °C; OCT3/4, fw:
ACATGTGTAAGCTGCGGCC, rev: GTTGTGCATAGTCGCTGCTTG, 58 °C;VEGF,
fw: TGACAGGGAAGAGGAGGAGA, rev: CGTCTGACCTGGGGTAGAGA, 59 °C;
PDGFA, fw: ACACGAGCAGTGTCAAGTGC, rev: GGCTCATCCTCACCTCACAT,
60 °C; PDGFRα, fw: GAAGCTGTCAACCTGCATGA, rev: CTTCCTTAGCACGG
ATCAGC, 57 °C; PDGFRβ, fw: GCACTTTTATCCACCCAGGA, rev: GTACTTGG
CTCAGCCTCCAG, 60 °C; CD31, fw: ATTGCAGTGGTTATCATCGGAGTG, rev:
CTCGTTGTTGGAGTTCAGAAGTGG, 58 °C; LEPTIN, fw: AAGCTTCAGGCT
ACTCCACA, rev: TGGAAGAGTGGCTTAGAGGA, 58 °C; SLUG, fw:
GAGCATTTGCAGACAGGTCA, rev: CCTCATGTTTGTGCAGGAGA, 58 °C; TWIST,
fw: TCTCGGTCTGGAGGATGGAG; rev: GTTATCCAGCTCCAGAGTCT, 58 °C. The
amplification products were separated on a 2% agarose gel in Tris-acetate EDTA
(TAE) buffer. The transcript amount of each gene was normalized to GAPDH.
Relative expression was calculated using Image J.
Western blot assay. For western blot analyses, cells were lysed in RIPA
buffer (50 mM Tris-HCl pH 7.2, 150 mM NaCl, 1% NP40, 0.1% SDS, 0.5% DOC,
1 mM PMSF, 25 mM MgCl2, and supplemented with a phosphatase inhibitor
cocktail). Protein concentration was determined by the BCA assay (Bio-Rad
Laboratories, Hercules, CA). Equivalent amounts of protein (50 μg) were
electrophoresed on 10% SDS–polyacrylamide gels. Precision Plus Protein™ Dual
Color Standards (Bio-Rad) were used to determine molecular weight. The gel was
electroblotted onto nitrocellulose membrane by using a Trans Blot Turbo system
(Bio-Rad) following the manufacturer’s instructions. The membrane was blocked
with 5% milk in TBS-0.1% Tween (TTBS) for 1 h at RT and washed with TTBS. The
membrane was then incubated with specific primary anti-human antibodies against
Smad-2/3 (1:1000; BD Pharmingen), p-Smad-2/3 (1:1000; Invitrogen, Life
Technologies Italia), CD31 (1:1000; Abcam), VEGF (1:1000; Santa Cruz
Biotechnology, Inc., Heidelberg, Germany) or β-Tubulin (1:5000; Abcam) overnight
at 4 °C. The membrane was then washed with TTBS and incubated with the
appropriate HRP-conjugated secondary antibody diluted 1:5000 in 3% milk in TTBS
for 1 h at RT. Membrane was then washed three times with TTBS. Immunoreactive
protein bands were visualized by the Pierce™ ECL Western Blotting Substrate
(Thermo Scientific, Milan, Italy) according to the manufacturer’s instructions. The
protein amount was normalized to tubulin. Relative expression was calculated using
Image J. Experiments were repeated three times with three triplicates for each
experiment.
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In vivo transplantation of cancer cells and hASCs. For in vivo
experiments, hASCs alone or MCF7 cells with hASCs were subcutaneously injected in
Balb/c nude mice. Mice were purchased from Charles River (Charles River Laboratories
International, Inc, Milan, Italy) and acclimatised for a week prior to experimentation.
Cancer cells and ASCs were enzymatically dissociated to obtain single-cell
suspensions, suspended in 0.2 ml of PBS, and injected subcutaneously in the right
flank of 6-week-old female Balb/c nudemice at a density of 1 × 106 cells. PBS alone was
administered in the left flank of mice as a control. Ten mice for group were used. The
day of injection was considered day 0. Xenograft tumours were measured and mice
were weighed once a week. After 30 days, mice were killed and tissues were collected,
fixed in buffered formalin and subsequently analysed by immunohistochemistry.
Tumour volume was determined by callipers with the following formula: (L ×W2)/
2 = mm3 where L and W are the longest and shortest perpendicular measurements
in millimeters, respectively. Tumour growth data were derived from three independent
experiments.
Hematoxylin and eosin (H&E) staining and immunohistochemical analyses for
Class I HLA, VEGF, CD31, vimentin and cytokeratin (all purchased from Abcam) were
performed to determine tumour histology and phenotype, using an Abcam Kit
(Abcam) and according to the manufacturer’s instructions. The injection experiments
were made in triplicate. This examination was performed according to our internal
ethics committee.
Statistical analysis. Experiments were performed in quadruplicates. Student’s
t-test (two-tailed) was used for statistical evaluation. Data from at least three independent
experiments are represented as mean±S.E.M. Level of significance was set at Po0.05.
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